2023. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s119. DOI:https://doi.org/10.25251/skin.7.supp.119.